PTE - PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE (PTE) soars 25% premarket after announcing preliminary topline data demonstrating that a randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care ((SOC)) vs SOC alone met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction ((PAR)) at 12 weeks.100 patients were evaluated with 50 patients receiving SkinTE plus SOC and 50 patients receiving SOC alone. Primary Endpoint: 70% of patients receiving SkinTE plus SOC had wound closure at 12 weeks versus 34% of patients receiving SOC alone—p=0.00032 Secondary Endpoint: PAR at 12 weeks was significantly greater for the SkinTE plus SOC treatment group (84.4%) vs SOC alone (53.5%)—p=0.00024 The results from this fully-enrolled 100 patient trial will be issued via a poster presentation at the Symposium on Advanced Wound Care ((SAWC)) Spring Conference held May 10-14, 2021.PolarityTE also plans to discuss the topline results during its earnings call

For further details see:

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint